Amgen’s supplemental New Drug Application of Kyprolis in combination with steroid medication dexamethasone or with Celgene’s approved multiple myeloma drug, Revlimid (lenalidomide) plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy has received FDA approval.